Myelodysplastic Syndrome from Theoretical Review to Clinical Application View

Overview

Journal Oncol Rev

Specialty Oncology

Date 2019 Jan 5

PMID 30607219

Citations 16

Authors

Amrallah A Mohammad

Affiliations

Soon will be listed here.

Abstract

Myelodysplastic syndromes (MDS), called ineffective hematopoiesis is indicated by bone marrow failure and tendency to acute myeloid leukemia transformation. Since the disease is more common in elderly with non- hematology co-morbidities, the research for less toxic and curative novel agents is essential. More than 12 years without new Food and Drug Administration approved drugs in MDS management through the whole course, only 5 drugs. We summarized the basic data in diagnosis, treatment guidelines and future direction.

Citing Articles

Research Progress on Pyroptosis in Hematological Malignancies.

Lyu T, Yin Q Curr Treat Options Oncol. 2023; 24(10):1439-1450.

PMID: 37635159 PMC: 10547621. DOI: 10.1007/s11864-023-01119-7.

A familial variant present in pediatric myelodysplastic syndrome.

Rahim M, Rahrig A, Overholt K, Conboy E, Czader M, Saraf A Cold Spring Harb Mol Case Stud. 2023; 9(2).

PMID: 37160314 PMC: 10240840. DOI: 10.1101/mcs.a006256.

Two Cases of Hemophagocytic Lymphohistiocytosis Associated with Disseminated Histoplasmosis Presented with Transient Pancytopenia.

Apriany N, Sukorini U, Ratnaningsih T, Asdie R, Subronto Y, Hutajulu S Case Rep Med. 2023; 2022:9521128.

PMID: 36620355 PMC: 9812595. DOI: 10.1155/2022/9521128.

The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?.

Snow A, Zeidner J Ther Adv Hematol. 2022; 13:20406207221112899.

PMID: 35898435 PMC: 9310330. DOI: 10.1177/20406207221112899.

Acquired spherocytosis in the setting of myelodysplasia.

Karlsson L, Mottelson M, Helby J, Petersen J, Glenthoj A Leuk Res Rep. 2022; 17:100332.

PMID: 35720514 PMC: 9198317. DOI: 10.1016/j.lrr.2022.100332.

References

ElNahass Y, Youssif L . Cytogenetic features in primary myelodysplastic syndrome Egyptian patients. J Adv Res. 2018; 10:77-83. PMC: 6057444. DOI: 10.1016/j.jare.2018.02.002. View

Junqueira F, Fernandes J, M Cunha G, Kubo T, Lima C, B P Lima D . Right and left ventricular function and myocardial scarring in adult patients with sickle cell disease: a comprehensive magnetic resonance assessment of hepatic and myocardial iron overload. J Cardiovasc Magn Reson. 2013; 15:83. PMC: 3848779. DOI: 10.1186/1532-429X-15-83. View

Silverman L, McKenzie D, Peterson B, Holland J, Backstrom J, Beach C . Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006; 24(24):3895-903. DOI: 10.1200/JCO.2005.05.4346. View

Fukumoto J, Greenberg P . Management of patients with higher risk myelodysplastic syndromes. Crit Rev Oncol Hematol. 2005; 56(2):179-92. DOI: 10.1016/j.critrevonc.2005.04.006. View

Sloand E, Wu C, Greenberg P, Young N, Barrett J . Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol. 2008; 26(15):2505-11. PMC: 6422026. DOI: 10.1200/JCO.2007.11.9214. View

Greenberg P, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F . Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12):2454-65. PMC: 4425443. DOI: 10.1182/blood-2012-03-420489. View

Kuendgen A, Lauseker M, List A, Fenaux P, Giagounidis A, Brandenburg N . Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia. 2012; 27(5):1072-9. PMC: 3650492. DOI: 10.1038/leu.2012.369. View

Swaminathan M, Borthakur G, Kadia T, Ferrajoli A, Alvarado Y, Pemmaraju N . A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure. Leuk Lymphoma. 2019; 60(9):2207-2213. DOI: 10.1080/10428194.2019.1576873. View

Brunner A, Steensma D . Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches. Clin Adv Hematol Oncol. 2018; 16(1):56-66. PMC: 6629038. View

10.

Goldberg H, Lusk E, Moore J, Nowell P, Besa E . Survey of exposure to genotoxic agents in primary myelodysplastic syndrome: correlation with chromosome patterns and data on patients without hematological disease. Cancer Res. 1990; 50(21):6876-81. View

11.

Fenaux P, Mufti G, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A . Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10(3):223-32. PMC: 4086808. DOI: 10.1016/S1470-2045(09)70003-8. View

12.

Bains A, Luthra R, Medeiros L, Zuo Z . FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia. Am J Clin Pathol. 2010; 135(1):62-9. DOI: 10.1309/AJCPEI9XU8PYBCIO. View

13.

Malcovati L, Della Porta M, Strupp C, Ambaglio I, Kuendgen A, Nachtkamp K . Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica. 2011; 96(10):1433-40. PMC: 3186303. DOI: 10.3324/haematol.2011.044602. View

14.

Hasserjian R, Campigotto F, Klepeis V, Fu B, Wang S, Bueso-Ramos C . De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study. Am J Hematol. 2014; 89(11):E193-9. DOI: 10.1002/ajh.23808. View

15.

Giraldo P, Nomdedeu B, Loscertales J, Requena C, de Paz R, Tormo M . Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. Cancer. 2006; 107(12):2807-16. DOI: 10.1002/cncr.22343. View

16.

Jerez A, Clemente M, Makishima H, Rajala H, Gomez-Segui I, Olson T . STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood. 2013; 122(14):2453-9. PMC: 3790512. DOI: 10.1182/blood-2013-04-494930. View

17.

Jadersten M, Malcovati L, Dybedal I, Della Porta M, Invernizzi R, Montgomery S . Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008; 26(21):3607-13. DOI: 10.1200/JCO.2007.15.4906. View

18.

Sperr W, Wimazal F, Kundi M, Baumgartner C, Nosslinger T, Makrai A . Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol. 2009; 21(1):114-9. DOI: 10.1093/annonc/mdp258. View

19.

Naqvi K, Garcia-Manero G, Sardesai S, Oh J, Vigil C, Pierce S . Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol. 2011; 29(16):2240-6. PMC: 3107743. DOI: 10.1200/JCO.2010.31.3353. View

20.

Nolte F, Hofmann W . Molecular mechanisms involved in the progression of myelodysplastic syndrome. Future Oncol. 2010; 6(3):445-55. DOI: 10.2217/fon.09.175. View